Skip to main content

Immunome, Inc. (IMNM)

NASDAQ: IMNM · IEX Real-Time Price · USD
25.78 -0.10 (-0.39%)
Sep 24, 2021 11:40 AM EDT - Market open
Market Cap275.27M
Revenue (ttm)n/a
Net Income (ttm)-21.59M
Shares Out11.81M
EPS (ttm)-2.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume73,833
Open25.88
Previous Close25.88
Day's Range25.00 - 26.19
52-Week Range9.28 - 63.78
Betan/a
AnalystsStrong Buy
Price Target36.00 (+39.6%)
Est. Earnings DateNov 15, 2021

About IMNM

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

IndustryBiotechnology
IPO DateOct 2, 2020
Employees23
Stock ExchangeNASDAQ
Ticker SymbolIMNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 36.00, which is an increase of 39.64% from the latest price.

Price Target
$36.00
(39.64% upside)
Analyst Consensus: Strong Buy

News

Immunome to Present at the Cantor Global Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Cantor Global Healthcare Conference

1 day ago - Business Wire

Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

1 week ago - Business Wire

Immunome's COVID-19 Antibody Neutralizes Two Variant Strains In Animal Studies

Immunome Inc's (NASDAQ: IMNM) three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants in preclinical te...

2 weeks ago - Benzinga

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

2 weeks ago - Business Wire

Immunome Reports Second Quarter 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Second Quarter 2021 Financial Results

1 month ago - Business Wire

LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Clips Is Plunging Today

Life Clips (LCLP) stock is falling on Tuesday following an update from the battery company about its recent business announcements. The post LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Cli...

Other symbols:NRBO
2 months ago - InvestorPlace

Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...

Other symbols:MRNANRBONVAXOCGNQDEL
2 months ago - InvestorPlace

IMNM Stock: The Covid Treatment News That Has Immunome Soaring Today

IMNM stock is having a great day today. The company is preparing to move forward with expedited testing for its delta variant treatment.

2 months ago - InvestorPlace

Why Immunome's Stock Is Soaring Today

Immunome Inc (NASDAQ:IMNM) is surging Tuesday morning after the company reported the pre-clinical testing results of its antibody cocktail.  Immunome announced that its three-antibody cocktail, IMM-BCP-...

2 months ago - Benzinga

Immunome Stock Jumps As COVID-19 Antibody Shows Preclinical Neutralizing Activity Against Delta Variant

Immunome Inc (NASDAQ: IMNM) has announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing.  ...

2 months ago - Benzinga

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

2 months ago - Business Wire

Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

2 months ago - Business Wire

Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

EXTON, Pa.--(BUSINESS WIRE)--Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

2 months ago - Business Wire

Immunome Appoints Franklyn G. Prendergast, M.D.

EXTON, Pa.--(BUSINESS WIRE)--Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors

3 months ago - Business Wire

Immunome to Present at the Jefferies Virtual Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Jefferies Virtual Healthcare Conference

3 months ago - Business Wire

Immunome Secures Additional $4.3M Funding From DoD To Develop COVID-19 Antibody Cocktail

Immunome Inc (NASDAQ: IMNM) has secured additional funding of $4.3 million from the Department of Defense (DoD) for the development of an antibody cocktail (IMM-BCP-01) to combat SARS-CoV-2 and its vari...

4 months ago - Benzinga

Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Va...

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

4 months ago - Business Wire

Immunome Reports First Quarter 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports First Quarter 2021 Financial Results

4 months ago - Business Wire

Immunome Raises $27M Via Private Equity Placement At 9%

In addition to encouraging preclinical data from the COVID-19 antibody cocktail announced today, Immunome Inc (NASDAQ: IMNM) has entered into a private placement agreement of approximately $27 million w...

4 months ago - Benzinga

Immunome's Stock Jumps On Its Antibody Cocktail Neutralizing Multiple COVID-19 Variants In Animal Studies

Immunome Inc (NASDAQ: IMNM) has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its ...

4 months ago - Benzinga

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Tes...

EXTON, Pa.--(BUSINESS WIRE)--Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Heads Toward IND Filing

4 months ago - Business Wire

Immunome Announces $27 Million Private Placement

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces $27 Million Private Placement

4 months ago - Business Wire

Immunome Appoints Corleen Roche as Chief Financial Officer

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces the appointment of Corleen Roche as Chief Financial Officer

5 months ago - Business Wire

Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Dennis Giesing, Ph.D. to the role of Chief Development Officer

5 months ago - Business Wire

Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody th...

5 months ago - Business Wire